Teprotumumab for Asymmetric Thyroid Eye Disease

      A 53-year-old woman presented with a 3-month history of markedly asymmetric thyroid eye disease with clinical activity scores (CAS) of 7 in her right eye (OD) and 1 in her left eye (OS). She had no diplopia. Exophthalmometry measured 27 mm OD and 18 mm OS (Fig A-F). Best corrected visual acuity was 20/20 in both eyes (OU). Following 8 infusions of teprotumumab over 24 weeks, exophthalmometry was 22 mm OD and 17 mm OS, CAS was 1 OU, and her appearance was more symmetrical. Teprotumumab may act differentially on the worse affected orbit and may therefore improve asymmetry (Magnified version of Fig A-F is available online at
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect